» Articles » PMID: 37622178

Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink

Overview
Journal Schizophr Bull
Specialty Psychiatry
Date 2023 Aug 25
PMID 37622178
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Hypothesis: Antipsychotics are first-line drug treatments for schizophrenia. When antipsychotic monotherapy is ineffective, combining two antipsychotic drugs is common although treatment guidelines warn of possible increases in side effects. Risks of metabolic side effects with antipsychotic polypharmacy have not been fully investigated. This study examined associations between antipsychotic polypharmacy and risk of developing diabetes, hypertension, or hyperlipidemia in adults with schizophrenia, and impact of co-prescription of first- and second-generation antipsychotics.

Study Design: A population-based prospective cohort study was conducted in the United Kingdom using linked primary care, secondary care, mental health, and social deprivation datasets. Cox proportional hazards models with stabilizing weights were used to estimate risk of metabolic disorders among adults with schizophrenia, comparing patients on antipsychotic monotherapy vs polypharmacy, adjusting for demographic and clinical characteristics, and antipsychotic dose.

Study Results: Median follow-up time across the three cohorts was approximately 14 months. 6.6% developed hypertension in the cohort assembled for this outcome, with polypharmacy conferring an increased risk compared to monotherapy, (adjusted Hazard Ratio = 3.16; P = .021). Patients exposed to exclusive first-generation antipsychotic polypharmacy had greater risk of hypertension compared to those exposed to combined first- and second-generation polypharmacy (adjusted HR 0.29, P = .039). No associations between polypharmacy and risk of diabetes or hyperlipidemia were found.

Conclusions: Antipsychotic polypharmacy, particularly polypharmacy solely comprised of first-generation antipsychotics, increased the risk of hypertension. Future research employing larger samples, follow-up longer than the current median of 14 months, and more complex methodologies may further elucidate the association reported in this study.

Citing Articles

The prevalence of chronic kidney disease in people with severe mental illness: A systematic review protocol.

Carswell C, Bramham K, Chilcot J, Jacobs R, Osborn D, Siddiqi N PLoS One. 2025; 20(1):e0310568.

PMID: 39888957 PMC: 11785261. DOI: 10.1371/journal.pone.0310568.


Aripiprazole, but Not Olanzapine, Alters the Response to Oxidative Stress in Fao Cells by Reducing the Activation of Mitogen-Activated Protein Kinases (MAPKs) and Promoting Cell Survival.

Kramar B, Marolt T, Yilmaz Goler A, Suput D, Milisav I, Monsalve M Int J Mol Sci. 2024; 25(20).

PMID: 39456900 PMC: 11508229. DOI: 10.3390/ijms252011119.


A Scoping Review of the Intersectionality of Autism and Intellectual and Developmental Disability with Social Inequity on Diagnosis and Treatment of Youth.

Weiss M, Daniolos P, Coughlin K, Mulvaney-Day N, Cook B, Rosenblum D J Child Adolesc Psychopharmacol. 2024; 34(7):292-301.

PMID: 38957953 PMC: 11807874. DOI: 10.1089/cap.2023.0058.

References
1.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz W . World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012; 13(5):318-78. DOI: 10.3109/15622975.2012.696143. View

2.
Tandon R, Keshavan M, Nasrallah H . Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008; 102(1-3):1-18. DOI: 10.1016/j.schres.2008.04.011. View

3.
Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A . The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol. 2011; 26(6):291-302. DOI: 10.1097/YIC.0b013e32834a5bf6. View

4.
Rognoni C, Bertolani A, Jommi C . Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. Clin Drug Investig. 2021; 41(4):303-319. PMC: 8004512. DOI: 10.1007/s40261-021-01000-1. View

5.
Stahl S . Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125(5):349-51. DOI: 10.1111/j.1600-0447.2012.01841.x. View